The buy includes a library of related clinical data as well as VuComp’s key personnel and existing customer base. iCad had previously acquired VuComp’s M-Vu breast density software product in April last year.
“This acquisition strongly complements iCAD’s strategy and will help accelerate our efforts to bring new and innovative cancer detection and workflow solutions to market, particularly as we prepare to launch our tomosynthesis cancer detection solutions. The addition of VuCOMP’s leading researchers and engineers to the iCAD team also represents an important resource for our deep learning technology initiatives aimed at creating improved solutions to help healthcare providers detect cancer early and positions us to maintain and expand our leadership position in the industry in the years ahead,” CEO Ken Ferry said in a press release.
iCad said it will continue to provide support services to VuComp M-Vu customers, as well as new opportunities to its customers to use the newly acquired solutions.
Last July, iCad said it launched its iReveal breast density software designed to deliver reproducible breast density assessments. The module was designed to be used with the company’s PowerLook advanced mammography platform.
The software will help treat an estimated 40% of women in the U.S. who have dense breast tissue that can mask the presence of cancer during standard mammography, the Nashua, N.H.-based company said.